Target overview
Synonyms
BCMA|TNFRSF17
Early Watch
BCMA / TNFRSF17
BCMA / TNFRSF17 is flagged as early watch based on 2 active trials across 2 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 2
Active trials: 2
Recruiting trials: 0
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 2
Top sponsors: GlaxoSmithKline | Centre Hospitalier Universitaire de Saint Etienne
Tumor types: Multiple Myeloma | Myeloma Multiple
Patent-density signal summary
Patent layer
Signal count: 0
Recent signals: 0
Top assignees: Unknown
Signal types: Unknown
Scores and labels
Deterministic summary
Clinical crowding: 1/5 (Low)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 2/5 (Watch)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.